Search Results

Deals

AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma

AbbVie (NYSE: ABBV) announced today that it has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer.

July 15, 2019

·

2 min read

Business

Now & Next Issue 1: Jubilant MavuPharma Q&A with Michael Gallatin

Saurabh Kapure, Vice President, Business Development, USA for Jubilant Biosys, recently sat down with Michael Gallatin, Ph.D., president and co-founder of Mavupharma (Mavu), the drug discovery and development company, to discuss some of the latest developments in the industry and at Mavu.

August 30, 2019

·

1 min read

BioForest

Mavupharma Selects First Immuno-Oncology Clinical Candidate MAVU-104, an Oral STING Pathway Enhancer

Mavupharma (Mavu) announced today that it has selected its first immuno-oncology clinical development candidate, MAVU-104, a novel innate immune modulator.

January 3, 2019

·

2 min read

Intrexon Enters Into $100M Preferred Stock Equity

BioForest

Frazier-Backed Mavupharma Scores $20M to Fund STING Program

The Series A funding will be used primarily to advance Mavu’s lead drug candidates into the clinic.

November 29, 2017

·

2 min read

Business

Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

Phathom Pharmaceuticals, Inc. today announced the appointment of James “Jamie” Topper, M.D., Ph.D., to its Board of Directors.

September 26, 2022

·

3 min read

Business

IniPharm Closes on $35 Million Series A to Fund NASH Drug Development

5AM Ventures and Wu Capital joined existing investors Frazier Healthcare Partners and Jubilant Biosys Limited.

November 11, 2020

·

3 min read

·

Mark Terry

BioForest

Inipharm Raises $35 Million in Series A to Focus on Highly Validated Genetic Target HSD17B13

-Initial therapeutic pipeline to target liver diseases -5AM Ventures and Wu Capital join existing investors Frazier Healthcare Partners and Jubilant Biosys Limited

November 11, 2020

·

3 min read

Pictured: A corporate building overlooking a freew

Business

Frazier Life Sciences Commits $1B to Nurturing New Biotech Companies

In total, FSI XI has netted over $987 million in commitments to drive the success of Frazier’s ongoing investment strategy.

March 16, 2022

·

2 min read

·

Jazmine Colatriano

Business

AbbVie Dives into STING and Boehringer Ingelheim Snaps Up Swiss-based AMAL

The M&A moves are expected to increase the oncology pipelines of both companies.

July 15, 2019

·

3 min read

·

Alex Keown

Interleukin-2 Market: Notable Developments and Competitive Landscape

Interleukin-2 is a novel procedure that has shown promising results in treatment of autoimmune disorder, blood cancer, ovarian cancer and renal cell.

April 23, 2021

·

4 min read